DX-2507

DX-2507 is a fully human monoclonal antibody antagonist of the neonatal Fc receptor (FcRn), originally developed by Dyax and later part of Takeda’s antibody therapeutics research portfolio.[2][5][10] By binding FcRn with high affinity at both neutral and acidic pH and sterically occluding the IgG Fc binding site, DX-2507 prevents FcRn-mediated recycling of IgG without affecting albumin binding, thereby accelerating IgG catabolism and lowering circulating IgG levels in preclinical models.[1][2][5][9] This pH‑insensitive FcRn blockade is being explored as a strategy for treating IgG‑mediated autoimmune diseases where pathogenic autoantibodies drive disease pathology.[2][5][11]